ANGLE Plc is a holding company, which engages in the provision of its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 119 full-time employees. The company went IPO on 2004-03-17. Its CTC harvesting technology, known as the Parsortix PC1 System, enables complete downstream analysis of the sample, including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. The Parsortix PC1 system is an in vitro diagnostic device intended to enrich CTCs from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The company offers the Portrait+ CTC Staining Kit, which is a ready-to-use laboratory kit for the identification, characterization and enumeration of epithelial and mesenchymal circulating tumor cells, including those undergoing epithelial-to-mesenchymal transition. Its Parsortix PR1 System is a semi-automated platform for epitope-independent CTC isolation, used in research and clinical trials for multiple cancer types.
Follow-Up Questions
ANPCF 주식의 가격 성능은 어떻습니까?
ANPCF의 현재 가격은 $0.025이며, 전 거래일에 decreased 0% 하였습니다.
Angle PLC의 주요 사업 주제나 업종은 무엇입니까?
Angle PLC은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Angle PLC의 시가총액은 얼마입니까?
Angle PLC의 현재 시가총액은 $8.0M입니다
Angle PLC는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Angle PLC에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 6명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
